HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel.

Abstract
Aurora-A kinase is a one of the key regulators during mitosis progression. Aurora-A kinase is a potential target for anticancer therapies because overexpression of Aurora-A, which is frequently observed in some human cancers, results in aberrant mitosis leading to chromosomal instability and possibly tumorigenesis. MK-5108 is a novel small molecule with potent inhibitory activity against Aurora-A kinase. Although most of the Aurora-kinase inhibitors target both Aurora-A and Aurora-B, MK-5108 specifically inhibited Aurora-A kinase in a panel of protein kinase assays. Inhibition of Aurora-A by MK-5108 in cultured cells induced cell cycle arrest at the G(2)-M phase in flow cytometry analysis. The effect was confirmed by the accumulation of cells with expression of phosphorylated Histone H3 and inhibition of Aurora-A autophosphorylation by immunostaining assays. MK-5108 also induced phosphorylated Histone H3 in skin and xenograft tumor tissues in a nude rat xenograft model. MK-5108 inhibited growth of human tumor cell lines in culture and in different xenograft models. Furthermore, the combination of MK-5108 and docetaxel showed enhanced antitumor activities compared with control and docetaxel alone-treated animals without exacerbating the adverse effects of docetaxel. MK-5108 is currently tested in clinical trials and offers a new therapeutic approach to combat human cancers as a single agent or in combination with existing taxane therapies.
AuthorsToshiyasu Shimomura, Shinichi Hasako, Yoko Nakatsuru, Takashi Mita, Koji Ichikawa, Tsutomu Kodera, Takumi Sakai, Tadahiro Nambu, Mayu Miyamoto, Ikuko Takahashi, Satomi Miki, Nobuhiko Kawanishi, Mitsuru Ohkubo, Hidehito Kotani, Yoshikazu Iwasawa
JournalMolecular cancer therapeutics (Mol Cancer Ther) Vol. 9 Issue 1 Pg. 157-66 (Jan 2010) ISSN: 1538-8514 [Electronic] United States
PMID20053775 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • 4-(3-chloro-2-fluorophenoxy)-1-((6-(1,3-thiazol-2-ylamino)pyridin to 2-yl)methyl) cyclohexanecarboxylic acid
  • Antineoplastic Agents
  • Cyclohexanecarboxylic Acids
  • Protein Kinase Inhibitors
  • Taxoids
  • Thiazoles
  • Docetaxel
  • AURKB protein, human
  • Aurka protein, mouse
  • Aurka protein, rat
  • Aurkb protein, mouse
  • Aurkb protein, rat
  • Aurora Kinase A
  • Aurora Kinase B
  • Aurora Kinases
  • Protein Serine-Threonine Kinases
Topics
  • Animals
  • Antineoplastic Agents (administration & dosage, chemistry, pharmacology)
  • Antineoplastic Combined Chemotherapy Protocols (pharmacology)
  • Aurora Kinase A
  • Aurora Kinase B
  • Aurora Kinases
  • Cell Death (drug effects)
  • Cell Line, Tumor
  • Cell Proliferation (drug effects)
  • Cyclohexanecarboxylic Acids (administration & dosage, chemistry, pharmacology)
  • Docetaxel
  • Humans
  • Inhibitory Concentration 50
  • Mice
  • Mitosis (drug effects)
  • Protein Kinase Inhibitors (administration & dosage, chemistry, pharmacology)
  • Protein Serine-Threonine Kinases (antagonists & inhibitors)
  • Rats
  • Taxoids (pharmacology, toxicity)
  • Thiazoles (administration & dosage, chemistry, pharmacology)
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: